Naloxone Prescribing in Primary Care Why, Who, and How Diana Coffa, MD Associate Professor, UCSF Family and Community Medicine CSAM Webinar 5/19/17

No Disclosures

Objectives

By the end of this session, you should be able to:

- Explain the evidence for overdose prevention with naloxone
- Discuss the impact of naloxone prescribing on patient and prescriber behavior
- Implement practical strategies for making naloxone available to at-risk patients in primary care settings


Poll Question


How many times have you prescribed naloxone for patients receiving opioid prescriptions?


- a) Never
- b) 1-5 times
- c) 5-10 times
- d) >10 times

Outline

- Why should I prescribe naloxone?
- To whom should I prescribe naloxone?
- How do I prescribe naloxone?







Layperson distribution

- AMA endorses naloxone provision²
- Since 1996, more than 150,000 people have received naloxone³
- Over 26,000 reversals

Artists: Mike Reger, Erin Ruch **Location:** Clarion Alley and Valencia St, San Francisco




Layperson distribution


- AMA endorses naloxone provision²
- Since 1996, more













What about for people who don't inject?

- Epidemiology is different
 - More likely to use alone
 - Less clearly defined community







Poll Question

Which of these is a known impact of naloxone prescribing?

- a) Prescribers give higher doses
- b) Patients feel insulted by the offer
- c) Patients are cautious with opioid
- d) Patients overdose on naloxone

Correct Answer

Which of these is a known impact of naloxone prescribing?

c) Patients are cautious with opioid

Prescribing Naloxone Impacts Prescriber Behavior⁶


 Total MEQ dropped 15% on average in the visit after naloxone prescription


Prescribing Naloxone Impacts Prescriber Behavior⁶


 Total MEQ dropped 15% on average in the visit after naloxone prescription


How does prescribing naloxone affect your opioid
prescribing?


p		
	Number	%
No effect	80	72.1
Might prescribe less	25	22.5
Might prescribe more	4	3.6











Patients think naloxone is a good idea

- 95% of patients said they would want a naloxone prescription in the future
- 97% said it should be prescribed to patients with opioid prescriptions



Poll Question

Who should receive naloxone? A patient on opioids who is/has

- a) Also taking benzodiazepines
- b) Taking 120 mg morphine per day
- c) Alcohol abuse hist., in remission
- d) All of the above

Correct Answer

Who should receive naloxone? A patient on opioids who is/has

d) All of the above

CDC Guidelines for Managing Chronic Pain⁸

- Consider offering naloxone when factors that increase risk of overdose are present. e.g.
 - History of overdose
 - History of substance use disorder
 - ≥50 MME/day
 - concurrent benzodiazepine use



Or should everyone prescribed opioids also be prescribed naloxone?

Safe medication



Or should everyone prescribed opioids also be prescribed naloxone?


- · Safe medication
- Positive behavior changes

I've probably been a little more cautious. Just being careful to take the right amount, count the hours... just thinking more cautiously about dosing.

I think if any opioid's prescribed at all that they definitely should make the patient get [naloxone] cause it's very useful especially for us with kids

Or should everyone prescribed opioids also be prescribed naloxone?

- Safe medication
- Positive behavior changes
- Everyone is at some risk of overdose⁹



Or should everyone prescribed opioids also be prescribed naloxone?

- Safe medication
- Positive behavior changes
- Everyone is at some risk of overdose
- Simplicity



- Or should everyone prescribed opioids also be prescribed naloxone?
- Safe medication
- Positive behavior changes
- Everyone is at some risk of overdose
- Simplicity
- Stigma¹⁰

And a lot of the times, like, they already feel like people think that they're a drug seeker so, like, bringing up that conversation [offering naloxone] kind of like makes me feel uncomfortable, like I'm accusing them of something, but it's really just, like, about a safety thing

- Or should everyone prescribed opioids also be prescribed naloxone?
- · Safe medication
- Positive behavior changes
- Everyone is at some risk of overdose
- Simplicity
- Stigma¹⁰

And a lot of the times, like, they already feel like people think that they're a drug seeker so, like, bringing up that conversation [offering naloxone] kind of like makes me feel uncomfortable, like I'm accusing them of something, but it's really just, like, about a safety thing

They are going to call my doctor and say I am abusing my pill, and they are going to want to do this, and they are going to want to do that, and you are red flagged if you ask for it.

- Or should everyone prescribed opioids also be prescribed naloxone?
- Safe medication
- Positive behavior changes
- Everyone is at some risk of overdose
- Simplicity
- Stigma¹⁰

And a lot of the times, like, they already feel like people think that they're a drug seeker so like bringing up that If it was up to me, every single opiate kind of prescription that was being filled like I'm

prescription that was being filled would also be dispensed with Narcan. Even if the patients aren't using them or the families aren't using it, it would help, I think, to over time kind of reduce the stigma and that Narcan is only for heroin

my pill, and they are going to want to do this, and they are going to want to do that, and you are red flagged if you ask for it.

's really

How to prescribe naloxone in California

Discussing naloxone with patients who are prescribed opioids

- Normalize
 - "These medicines can be very strong and it's easy to have a bad reaction to them. So I give all of my patients this antidote in case that happens."
- Avoid the word "overdose"
 - Patients equate it with heroin, addiction, and illicit use
 - They do not identify as being at risk for overdose.

Overdose

- In one study¹⁰: 22/60 (37%) patients with long term opioid prescriptions had stopped breathing and required help to wake up
 - 45% of those people did not describe themselves as having overdosed

An interview from that study

- Interviewer: How many times would you say you've had these bouts of delirium, or you've stopped breathing because of opioids?
- · Patient: Ever? Eight to 10 times.
- I: And how many times has [naloxone] been used on you?
- P: Oh, boy. That would be really hard to answer. I'd say somewhere in the neighborhood of 12 to 15 times.
- I: So, around 12 to 15 times someone has given you [naloxone] because you've stopped breathing because of opioids?
- P: Yes. Medical staff each time. Because of the opioids, I've stopped breathing.
- I: Over what period of time?
- P: Over 1 year.

An interview from that study

- Interviewer: How many times would you say you've had these bouts of delirium, or you've stopped breathing because of opioids?
- Patient: Ever? Eight to 10 times.
- I: And how many times has [naloxone] been used on you?
- P: Oh, boy. That would be really hard to answer. I'd say somewhere in the neighborhood of 12 to 15 times.
- I: So, around 12 to 15 times someone has given you [naloxone] because you've stopped breathing because of opioids?
- P: Yes. Medical staff each time. Because of the opioids, I've stopped breathing.
- I: Over what period of time?
- P: Over 1 year.

This patient denied ever having experienced an overdose

Suggested language when working with people who are prescribed opioids

"Opioids can sometimes slow or even stop your breathing."

"Naloxone is the antidote to opioids it can be used if there is a bad reaction where you can't be woken up."

"Naloxone is for opioid medication like an epinephrine pen is for someone with an allergy."

"Naloxone is important to have in the home in case someone is accidentally exposed to opioid painkillers."

Video: Talking about naloxone in a primary care or pain management setting

https://www.youtube.com/watch?v=F52K2GVCBtE

Logistics


- Who should initiate prescribing?
- Who should do the teaching? What kind of teaching is required?
- · Which formulation is covered?
- What do pharmacies carry?
- Am I at legal risk if I prescribe?

Who should initiate prescribing?

Many options


Providers







- Providers
- Nursing staff










- Providers
- Nursing staff
- Panel management
- Group visits




- Providers
- Nursing staff
- Panel management
- Group visits
- Pharmacists





- Providers
- Nursing staff
- Panel management
- Group visits
- Pharmacists
- Patients






Many options


- Providers
- Nursing staff
- Panel management
- Group visits
- Pharmacists
- Patients
- Public



Patient education

- Signs of overdose
- How to administer naloxone
- Call 911







The Prescription

MediCal covers 4 formulations

- Nasal Spray
 - Simplest: no injection, no assemb
 - High dose
 - Rx: 1 two-pack of two 4 mg/0.1 mL intranasal devices
 - Spray 0.1 mL into one nostril and call 911.
 Repeat with second device into other nostril after 2-3 minutes if no or minimal response.
 - NDC 69547-353-02

Also covered by MediCal

- Naloxone 0.4mg/ml vial + syringe
 - Requires injection
 - Least expensive option
 - Rx: #2 single-use 1 ml vials PLUS #2 3 mL syringe w/ 23-25 gauge 1-1.5 inch IM needles
 - Inject 1 mL in shoulder or thigh. Repeat after
 2-3 minutes if no or minimal response.
 - NDC 67457-0292-0200409-1215-01



Also covered by MediCal

- Naloxone 1mg/ml syringe
- Complicated assembly
- Requires the clinic or pharmacy to stock atomizers
- Atomizers not covered
- Requires teaching about atomizer assembly
- Rx: #2 Naloxone 1mg/ml with luerlock needleless syringe PLUS #2 mucosal atomizer devices (MAD 300)
- Spray 1 ml (1/2 of syringe) into each nostril.
 Repeat after 2-3 minutes if no or minimal response.
- NDC 76329-3369-01

Also covered by MediCal

- Naloxone 0.4mg syringe
 - Not recommended
 - Difficult to assemble
 - Requires injection



Prescribing Summary

- Program the intranasal rx into your EMR
- · Dose is the same for adults and children

	Product comparison							
	0 0							
FDA approved Labeling includes instructions for layperson use	X (for IV, IM, SC)	x x	х	x	x x			
Layperson experience	x		x		x			
Assembly required	x		x	x				
Fragile	X							
Can titrate dose	X		x	x				
Strength	1 mg/mL	4 mg/0.1 mL	0.4 mg/mL OR 4 mg/10 mL	0.4 mg/mL	0.4 mg/0.4mL			
Total volume of kit/package	4 mg/4 mL	8 mg/ 0.2 mL	0.8 mg/2 mL OR 4 mg/10 mL	0.8 mg/2 mL	0.8 mg/0.8 mL			
Storage requirements (All protect from light)	Store at 59-86 °F Fragile: Glass.	Store at 59-77 °F Excursions from 39-104 °F	Store at 68-77 °F Breakable: Glass.	Store at 68-77 °F Breakable: Glass.	Store at 59-77 °F Excursions from 39-104 °F			
Cost/kit ⁴	SS	SS	\$	\$	SSS ⁵			
	Prescription variation							
Refills	Two	Two	Two	Two	Two			

Prescribe to Prevent

PrescribeToPrevent.org

January 21, 20

Prescribing Summary

- Program the intranasal rx into your EMR
- · Dose is the same for adults and children

	Injectable (intranasal-		Intranasal branded ²	Injectable generic ³	Injectable generic	Auto-injector branded
Rx and quantity	#2 2 mL Luer-Jet™ Luer-Lock needleless syringe plus #2 mucosal atomizer devices (MAD-300)		#1 two-pack of two 4 mg/0.1 mL intranasal devices	#2 single-use 1 mL vials OR #1 10mL multidose vial PLUS #2 3 mL syringe w/ 23-25 gauge 1-1.5 inch IM needles	#2 single-use 1 ml vials PLUS #2 3 mL syringe w/ 23-25 gauge 1-1.5 inch IM needles	#1 two-pack of two 0.4 mg/0.4 mL prefilled auto-injector devices
Sig. (for suspected opioid overdose)	Spray 1 ml (1/2 of syringe) into each nostril. Repeat after 2- 3 minutes if no or minimal response.		Spray 0.1 mL into one nostril. Repeat with second device into other nostril after 2-3 minutes if no or minimal response.	Inject 1 mL in shoulder or thigh. Repeat after 2-3 minutes if no or minimal response.	Inject 1 mL in shoulder or thigh. Repeat after 2-3 minutes if no or minimal response.	Inject into outer thigh as directed by English voice-prompt system. Place black side firmly on outer thigh and depress and hold for 5 seconds. Repeat with second device in 2-3 minutes if no or minimal response.
			Ordering	information		
How supplied	Box of 10 Luer-Jet™ prefilled glass syringes		Two-pack of single use intranasal devices	Box of 10 single-dose fliptop vials (1 ml) OR Case of 25 multi-dose fliptop vials (10 ml)	Box of 10 single-dose fliptop vials	Two pack of single use auto-injectors + 1 trainer
Manufacturer	IMS/ Amphastar	Teleflex (IN adapter)	Adapt Pharma	Hospira	Mylan	kaléo
Web address	Amphastar. com	Teleflex. com	Narcannasalspray.com	Hospira.com	Mylan.com	Evzio.com
Customer service	800-423- 4136	866-246- 6990	844-462-7226	877-946-7747	724-514-1800	855-773-8946
NDC	76329- 3369-01	DME- no NDC	69547-353-02	00409-1215-01 (1 ml) 00409-1219-01 (10 ml)	67457-0292-02	60842-030-01

Pharmacy Issues

- Pharmacists can be champions of naloxone
 - Can dispense independently (AB 1535)
 - Can provide teaching
 - A pharmacist champion can help you communicate with local pharmacies
 - Consider contacting the regional manager



Pharmacy Issues

- Pharmacists can be champions of naloxone
 - Can dispense independently (AB 1535)
 - Can provide teaching
 - A pharmacist champion can help you communicate with local pharmacies
 - Consider contacting the regional manager
- Pharmacy may not carry it the first time you order
 - Can order within 1-2 days

Pharmacy Issues

- Pharmacists can be champions of naloxone
 - Can dispense independently (AB 1535)
 - Can provide teaching
 - A pharmacist champion can help you communicate with local pharmacies
 - Consider contacting the regional manager
- Pharmacy may not carry it the first time you order
 - Can order within 1-2 days
- Medi-Cal carve out
 - Some pharmacists may need coaching

Naloxone Access Law: CA AB635¹¹

 Providers are encouraged to prescribe naloxone to patients receiving a chronic opioid prescription.

Naloxone Access Law: CA AB635¹¹

- Providers are encouraged to prescribe naloxone to patients receiving a chronic opioid prescription.
- Naloxone can be prescribed to people on whom it is not intended to be used. It is legal to prescribe to potential witnesses.

Naloxone Access Law: CA AB635¹¹

- Providers are encouraged to prescribe naloxone to patients receiving a chronic opioid prescription.
- Naloxone can be prescribed to people on whom it is not intended to be used. It is legal to prescribe to potential witnesses.
- A licensed healthcare prescriber can issue a standing order for the dispensing of naloxone by healthcare or community workers.

Naloxone Access Law: CA AB635¹¹

- Providers are encouraged to prescribe naloxone to patients receiving a chronic opioid prescription.
- Naloxone can be prescribed to people on whom it is not intended to be used. It is legal to prescribe to potential witnesses.
- A licensed healthcare prescriber can issue a standing order for the dispensing of naloxone by healthcare or community workers.
- Lay persons can possess and administer naloxone to others during an overdose situation.

Key Resources

Patient education:


SFDPH patient brocure

Provider education:

SFDPH monograph

Prescribe To Prevent

CSAM naloxone webpage



References

- Walley A et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ, 2013; 346: f174.
- Increasing access to naloxone. https://www.ama-assn.org/delivering-care/increasing-access-naloxone Accessed Apr-2017.
- Wheeler E, Jones TS, Gilbert MK, Davidson PJ. Opioid Overdose Prevention Programs Providing Naloxone to Laypersons — United States, 2014. MMWR. CDC. June 19, 2015 / 64(23);631-635
- Coffin PO, Sullivan SD. Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal. Ann Intern Med. 2013;158(1):1-9.
- Coffin PO, Behar E, Rowe C, Santos GM, Coffa D, Bald M, Vittinghoff E. Nonrandomized intervention study of naloxone coprescription for primary care patients receiving long-term opioid therapy for pain. Ann Intern Med. 2016;164(4):245-252.
 Behar et al. Acceptability of Naloxone Co-Prescription Among Primary Care Providers
- Behar et al. Acceptability of Naloxone Co-Prescription Among Primary Care Providers Treating Patients on Long-Term Opioid Therapy for Pain. Journal of General Internal Medicine. March 2017, Volume 32, Issue 3, pp 291–295
- Behar E et al. Primary Care Patient Experience with Naloxone Prescription. Ann Fam Med September/October 2016 vol. 14 no. 5 431-436
- 8. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain United States, 2016. MMWR Recomm Rep 2016;65(No. RR-1):1–49.
- Liang Y, Turner BJ. Assessing risk for drug overdose in a national cohort: role for both daily and total opioid dose? J Pain. 2015 Apr; 16(4): 318–325.
- Green T et al. Perpetuating stigma or reducing risk? Perspectives from naloxone consumers and pharmacists on pharmacy-based naloxone in 2 states. JAPhA Mar-Apr 57:2. S19–S27
- San Francisco Department of Public Health. Naloxone for opioid safety: a provider's quide to prescribing naloxone to patients who use opioids. January 2015.





Thank you for participating in today's webinar.

Stay online after the webinar ends and you will be connected to the post webinar quiz and evaluation.

You will also receive a link via email.

